Method of treating cancer
Methods are provided of treating a human for cancer comprising administering at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof, to a patient, wherein said patient does not have one or more allelic polymorphisms selected from the group of: HLA-DQA1*0201, HLA-DQB1*0202, and HLA-DRB1*0701. Patients may also be free of genotypes in TNXB; rs12153855 and/or rs17207923.
1. A method of treating a human for breast cancer comprising:
(a) obtaining a biological sample from said human;
(b) detecting whether an allelic polymorphism at HLA-DRB1*0701 is present in said biological sample;
(c) determining that said human does not have an allelic polymorphism at HLA-DRB1*0701 based on detecting the absence of said allelic polymorphism in step (b); and
(d) administering at least one dose of lapatinib or a pharmaceutically acceptable salt or composition thereof to said human, thereby treating the human for breast cancer.
2. The method according to claim 1 , wherein lapatinib, or a pharmaceutically acceptable salt or composition thereof, is administered to said human as monotherapy.
3. The method according to claim 1 , wherein said lapatinib, or a pharmaceutically acceptable salt or composition thereof, is co-administered with at least one other anti-cancer agent.
4. The method according to claim 3 , wherein said at least one other anti-cancer agent is selected from the group of: trastuzumab, capecitabine, paclitaxel, carboplatin, pazopanib and letrozole.
5. The method according to claim 1 , further comprising determining that said human is not DQ2.2 seropositive where DQ 2.2 is not detected to be present in said human.
6. The method according to claim 1 , wherein said human does not show significant elevation in alanine aminotransferase (ALT) and/or total bilirubin (TBL) after the administration of at least one dose of lapatinib, or a pharmaceutically acceptable salt or composition thereof.